Alongside the favorable efficacy and safety profile observed in the NefIgArd trial,4 biomarker analyses from the earlier Phase 2 trial, The Effect of Nefecon in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease, have shown that nefecon reduces levels of Gd-IgA1 and IgA-containing immune complexes versus placebo,24 lending further support to a disease-modifying action. The gene discussed is CD79A; the disease is chronic kidney disease.